Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

High-Intensity Functional Training vs. Moderate-Intensity Continuous Training in Cardiovascular Disease Patients

keskiviikko 4. marraskuuta 2026 päivittänyt: Arlette Perry, University of Miami

A Comparison of Two Exercise Protocols on Vascular Function and Subclinical Predictors of Cardiovascular Risk in Patients With Cardiovascular Disease

The purpose of this study is to compare two exercise programs with a control group to see how they affect blood vessel health in people with cardiovascular disease.

Tutkimuksen yleiskatsaus

Tila

Ei vielä rekrytointia

Ehdot

Interventio / Hoito

Opintotyyppi

Interventio

Ilmoittautuminen (Arvioitu)

200

Vaihe

  • Ei sovellettavissa

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskeluyhteys

  • Nimi: Arlette Perry, PhD
  • Puhelinnumero: 305-898-7370
  • Sähköposti: aperry@miami.edu

Opiskelupaikat

  • Yhdysvallat
    • Florida
      • Coral Gables, Florida, Yhdysvallat, 33146
        • Merrick Building, University of Miami
        • Ottaa yhteyttä:

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

45 vuotta ja vanhemmat (Aikuinen, Vanhempi Aikuinen)

Hyväksyy terveitä vapaaehtoisia

Ei

Sukupuolet, jotka voivat opiskella

Kaikki

Kuvaus

Inclusion Criteria:

  • Age: ≥45 years.

  • Diagnosis of cardiovascular disease (CVD): Clinically documented by a licensed clinician in the medical record, including at least one of the following:

    1. Prior myocardial infarction (MI) or angiographically confirmed coronary artery disease (CAD).
    2. Stable angina, prior PCI/CABG, or documented myocardial ischemia on stress testing.

  • Clinical stability: On stable guideline-directed medical therapy (GDMT) for ≥2 weeks and no hospitalizations for acute cardiovascular events within the past 4 weeks.

  • For post-myocardial infarction (MI) participants: ≥4 weeks since index MI and clinically stable without ongoing ischemia.

  • Capacity and consent: Able to understand the study procedures and provide written informed consent (with interpreter support if needed).

  • Procedural feasibility: Able to undergo vascular ultrasound testing (e.g., flow-mediated dilation), pulse wave analysis/velocity, standard transthoracic echocardiography, body composition assessment, venipuncture for biomarkers, and submaximal fitness tests (e.g., 6-minute walk and handgrip).

  • Participants should be able to understand English or bring someone who speaks and understands English.

Exclusion Criteria:

  • Individuals who are not yet adults (infants, children, teenagers)

  • Pregnant women

  • Prisoners

  • Acute/unstable conditions (past 4 weeks): Acute coronary syndrome, decompensated heart failure, sustained ventricular arrhythmias, syncope of cardiac origin, or stroke/Transient Ischemic Attack (TIA).

  • Hemodynamic instability or severe uncontrolled disease:

    1. Resting Systolic Blood Pressure (SBP) ≥180 mmHg or Diastolic Blood Pressure (DBP) ≥110 mmHg at screening or visit day despite medication
    2. Oxygen saturation <90% at rest on room air
    3. Active myocarditis
    4. Active pericarditis

  • Valvular/structural heart disease likely to confound measures or increase risk: Severe aortic stenosis or severe valvular regurgitation; obstructive hypertrophic cardiomyopathy with resting Left Ventricular Outflow Tract (LVOT) gradient >30 mmHg; restrictive or constrictive physiology chronic or acute requiring urgent intervention

  • Arrhythmias that preclude accurate testing or pose risk: Rapid, uncontrolled atrial fibrillation/flutter (ventricular rate persistently >110 bpm at rest) or frequent ectopy that prevents reliable Doppler/strain or pulse-wave measurements. (Rate-controlled Atrial fibrillation (AF) is allowable if measurements are technically feasible.)

  • Recent major procedures: Major surgery, Percutaneous Coronary Intervention (PCI), or Coronary Artery Bypass Grafting (CABG) within the past 4 weeks (CABG within 8 weeks) unless cleared by the treating physician and study PI.

  • Severe non-cardiac comorbidities likely to confound vascular/endothelial markers or limit participation:

  • Active systemic infection or fever within 7 days; active autoimmune/inflammatory disease flare requiring escalation of immunosuppression in past 8 weeks.

  • Advanced renal dysfunction (eGFR <30 mL/min/1.73 m² or dialysis) or decompensated cirrhosis (Child-Pugh C).

  • Active malignancy receiving cytotoxic chemotherapy or thoracic radiation within the past 6 months (hormonal therapy permitted).

  • Contraindications to phlebotomy or vascular testing: Known severe bleeding diathesis or platelet count <50,000/μL; current therapeutic anticoagulation is permitted if clinically stable and venipuncture is not contraindicated by the treating clinician.

  • Peripheral vascular disease

  • Musculoskeletal/neurologic limitations preventing fitness testing (e.g., non-weight-bearing status, unstable orthopedic injuries) without safe alternatives.

  • Substance use or cognitive/psychiatric conditions that, in the investigator's judgment, would impair consent, adherence to pre-test restrictions, or completion of study procedures.

  • Current participation in another interventional trial that could affect vascular/endothelial outcomes (observational registries permitted).

  • Active participation in sports or exercise with 24-48 hours of testing.

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Ensisijainen käyttötarkoitus: Hoito
  • Jako: Satunnaistettu
  • Inventiomalli: Rinnakkaistehtävä
  • Naamiointi: Yksittäinen

Aseet ja interventiot

Osallistujaryhmä / Arm
Interventio / Hoito
Kokeellinen: High-intensity Functional Training (HIFT) Group

Participants assigned to the HIFT group will perform supervised high-intensity functional training using scalable, multi-joint functional movements three days per week for a total of 12 weeks.
Käyttäytyminen: High-Intensity Functional Training (HIFT)

Participants will complete supervised high-intensity functional training consisting of scalable, multi-joint functional movements. Exercise sessions will occur approximately 3 times per week for 12 weeks and will last 40 to 60 minutes, including warm-up and cool-down. Examples of activities may include body-weight exercises, resistance training, step-ups, sit-to-stand movements, squats, lunges, modified push-ups, and core exercises.
Kokeellinen: Moderate-Intensity Continuous Training (MICT) Group

Participants assigned to the MICT group will perform supervised moderate-intensity continuous aerobic exercise three days per week for a total of 12 weeks.
Käyttäytyminen: Moderate-Intensity Continuous Training (MICT)

Participants will complete supervised moderate-intensity continuous aerobic exercise. Exercise sessions will occur approximately 3 times per week for 12 weeks and will last 40 to 60 minutes, including warm-up and cool-down. Examples of activities may include treadmill walking, cycling, elliptical exercise, or step-based aerobic activity.
Ei väliintuloa: Control Group

Participants in this group will be asked to maintain their usual diet, usual medical care, physical activity, and lifestyle behaviors.

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Change in Carotid-Femoral Pulse Wave Velocity (cfPWV)
Aikaikkuna: Baseline and Week 12 (post-intervention)

Carotid-Femoral Pulse Wave Velocity (cfPWV) will be measured in meters per second (m/s) as an indicator of arterial stiffness. Measurement will be obtained using the SphygmoCor XCEL device (AtCor Medical) with upper arm and thigh cuffs with carotid artery applanation tonometry to assess pulse wave transit time.
Baseline and Week 12 (post-intervention)
Change in Central Augmentation Index (cAIx)
Aikaikkuna: Baseline and Week 12 (post-intervention)

Central Augmentation Index (cAIx) expressed as a percentage (%) will be assessed using the SphygmoCor XCEL device via pulse wave analysis of the central arterial waveform derived from carotid artery tonometry and peripheral blood pressure measurements.
Baseline and Week 12 (post-intervention)
Change in Mean Arterial Pressure (MAP)
Aikaikkuna: Baseline and Week 12 (post-intervention)

Mean Arterial Pressure (MAP) measured in millimeters of mercury (mmHg), will be estimated using the SphygmoCor XCEL device based on an algorithm derived from peripherally measured blood pressure obtained from an automated upper arm cuff.
Baseline and Week 12 (post-intervention)
Percent Change in Flow-Mediated Dilation (FMD)
Aikaikkuna: Baseline and Week 12 (post-intervention)

Flow-Mediated Dilation (FMD) will be measured using a Philips Affiniti 50 ultrasound system. FMD will be expressed as percent (%) change in brachial artery diameter from pre-occlusion baseline to peak dilation following a 5-minute forearm occlusion.
Baseline and Week 12 (post-intervention)
Change in Carotid Intima-Media Thickness (cIMT)
Aikaikkuna: Baseline and Week 12 (post-intervention)

Carotid Intima-Media Thickness (cIMT), measured in millimeters (mm), will be assessed using a Philips Affiniti 50 ultrasound system. High-resolution B-mode images of the distal common carotid artery will be acquired, and mean wall thickness will be calculated from standardized image segments of the left and right carotid arteries.
Baseline and Week 12 (post-intervention)

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Change in Body Mass Index (BMI)
Aikaikkuna: Baseline and Week 12 (post-intervention)

Change in body mass index (BMI), measured in kilograms per square meter (kg/m²), will be calculated as weight in kilograms divided by height in meters squared.
Baseline and Week 12 (post-intervention)
Change in Waist Circumference
Aikaikkuna: Baseline and Week 12 (post-intervention)

Change in waist circumference, measured in centimeters (cm), will be assessed using a standardized measuring tape.
Baseline and Week 12 (post-intervention)
Change in Body Fat Percentage
Aikaikkuna: Baseline and Week 12 (post-intervention)

Change in body fat percentage, measured as a percentage (%), will be assessed using the SECA mBCA bioelectrical impedance analysis system.
Baseline and Week 12 (post-intervention)
Change in Skeletal Muscle Mass
Aikaikkuna: Baseline and Week 12 (post-intervention)

Change in skeletal muscle mass, measured in kilograms (kg), will be assessed using the SECA mBCA bioelectrical impedance analysis system.
Baseline and Week 12 (post-intervention)
Change in Visceral Adipose Tissue
Aikaikkuna: Baseline and Week 12 (post-intervention)

Change in visceral adipose tissue, measured in liters, will be assessed using the SECA mBCA bioelectrical impedance analysis system.
Baseline and Week 12 (post-intervention)
Change in Handgrip Strength
Aikaikkuna: Baseline and Week 12 (post-intervention)

Handgrip strength will be assessed using a calibrated hydraulic hand dynamometer. Grip force will be recorded in kilograms (kg), with higher values indicating greater muscle strength.
Baseline and Week 12 (post-intervention)
Change in Cardiorespiratory Fitness (6-minute walk test (6MWT))
Aikaikkuna: Baseline and Week 12 (post-intervention)

Cardiorespiratory fitness is measured by the 6-Minute Walk Test (6MWT) as the total distance walked (meters) in six minutes.
Baseline and Week 12 (post-intervention)
Change in Nutritional Intake and Diet Quality
Aikaikkuna: Baseline and Week 12 (post-intervention)

Diet quality will be assessed using the Mini-EAT instrument. The Mini-EAT generates a total score ranging from 0 to 90 points, with higher scores indicating greater adherence to healthy dietary patterns and better overall diet quality.
Baseline and Week 12 (post-intervention)
Change in Depression Symptoms
Aikaikkuna: Baseline and Week 12 (post-intervention)

Depression symptoms will be assessed using the Patient Health Questionnaire-9 (PHQ-9). The PHQ-9 consists of 9 items with a total score ranging from 0 to 27, with higher scores indicating greater severity of depressive symptoms.
Baseline and Week 12 (post-intervention)
Change in Anxiety Symptoms
Aikaikkuna: Baseline and Week 12 (post-intervention)

Anxiety symptoms will be assessed using the Generalized Anxiety Disorder 7-item scale (GAD-7). The GAD-7 consists of 7 items with a total score ranging from 0 to 21, with higher scores indicating greater severity of anxiety symptoms.
Baseline and Week 12 (post-intervention)
Change in General Well-Being
Aikaikkuna: Baseline and Week 12 (post-intervention)

General well-being will be assessed using the World Health Organization-5 Well-Being Index (WHO-5). The WHO-5 consists of 5 items with a total raw score ranging from 0 to 25, with higher scores indicating better well-being.
Baseline and Week 12 (post-intervention)
Change in Composite Blood Lipid Profile
Aikaikkuna: Baseline and Week 12 (post-intervention)

A composite blood lipid score will be calculated using total cholesterol (mg/dL), low-density lipoprotein (LDL) cholesterol (mg/dL), high-density lipoprotein (HDL) cholesterol (mg/dL), and triglycerides (mg/dL) measurements obtained from blood samples collected and analyzed using standard clinical laboratory methods.
Baseline and Week 12 (post-intervention)
Change in High-Sensitivity C-Reactive Protein (hs-CRP)
Aikaikkuna: Baseline and Week 12 (post-intervention)

Change in high-sensitivity C-reactive protein (hs-CRP) levels, measured in milligrams per liter (mg/L), will be assessed from study blood draws and/or clinically obtained laboratory results when available and authorized.
Baseline and Week 12 (post-intervention)
Change in N-Terminal Pro-B-Type Natriuretic Peptide
Aikaikkuna: Baseline and Week 12 (post-intervention)

N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels, measured in picograms per milliliter (pg/mL), will be assessed from study blood draws and/or clinically obtained laboratory results when available and authorized.
Baseline and Week 12 (post-intervention)
Change in Glycosylated Hemoglobin (HbA1c)
Aikaikkuna: Baseline and Week 12 (post-intervention)

Hemoglobin A1c (HbA1c), measured as a percentage (%), will be assessed using study blood draws and/or clinically obtained laboratory results when available and authorized.
Baseline and Week 12 (post-intervention)

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Sponsori

University of Miami

Tutkijat

  • Päätutkija: Arlette Perry, PhD, University of Miami

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Arvioitu)

Perjantai 1. tammikuuta 2027

Ensisijainen valmistuminen (Arvioitu)

Lauantai 1. tammikuuta 2028

Opintojen valmistuminen (Arvioitu)

Lauantai 1. tammikuuta 2028

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Keskiviikko 4. marraskuuta 2026

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Keskiviikko 4. marraskuuta 2026

Ensimmäinen Lähetetty (Todellinen)

Tiistai 10. marraskuuta 2026

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Tiistai 10. marraskuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Keskiviikko 4. marraskuuta 2026

Viimeksi vahvistettu

Torstai 1. lokakuuta 2026

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Muita asiaankuuluvia MeSH-ehtoja

Muut tutkimustunnusnumerot

  • 20260737

Yksittäisten osallistujien tietojen suunnitelma (IPD)

Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?

EI

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Ei

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .

Tilaa